Recombinant viral vectors
AssigneeInternational AIDS Vaccine Initiative
InventorsChristopher L. Parks, Ivo Lorenz, Sanjay K. Phogat, Timothy J. Zamb
Life of this patent
Estimating the term…
Abstract
The present relation relates to recombinant vesicular stomatitis virus for use as prophylactic and therapeutic vaccines for infectious diseases of AIDS. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention.
Claims8
A chimeric EnvG protein comprising
- a vesicular stomatitis virus (VSV) G signal peptide,
- a human immunodeficiency virus (HIV) gp120 protein, and
- a HIV-VSV G gp41 fusion protein,
- wherein the VSV G signal peptide replaces an HIV Env signal peptide,
- wherein the gp41 fusion protein comprises a HIV gp41 protein, and
- wherein the membrane proximal external region (MPER), transmembrane (TM) and cytoplasmic tail (CT) of the HIV gp41 protein are replaced with a VSV G protein MPER, TM and CT.
A recombinant vesicular stomatitis virus (VSV) vector encoding a VSV G protein comprising a leader peptide, an ectodomain, a stem, a trans-membrane spanning domain and a cytoplasmic tail, wherein the VSV G protein harbors epitopes from an HIV Env membrane proximal external region (MPER) inserted into the stem region of VSV G protein, wherein the MPER sequence contains an insertion and/or substitution of HIV epitopes 2F5 comprising the sequence ELDKWASL and/or 4E10 comprising the sequence WFDITNWLWY.
Dependencies are inferred from the claim text.